Clinical Trial Update: A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating OL-101 injection in relapsed or refractory multiple myeloma is currently recruiting. The study is sponsored by Zhejiang Univ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• OL-101

Snippet

Sponsor: Zhejiang University | Conditions: Multiple Myeloma | Phase 1 | Status: RECRUITING